Alnylam Pharmaceuticals
ALNY
#871
Rank
A$41.31 B
Marketcap
A$308.80
Share price
-0.55%
Change (1 day)
-53.73%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$5.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$5.37. In 2025 the company made an earnings per share (EPS) of A$2.55.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.61119.94%
2025A$2.55
2023A-$5.00-62%
2022A-$13.1629.03%
2021A-$10.20-3.36%
2020A-$10.55-8.48%
2019A-$11.537.67%
2018A-$10.7139.74%
2017A-$7.6612.94%
2016A-$6.7938.84%
2015A-$4.89-32.88%
2014A-$7.28259.44%
2013A-$2.03-31.25%
2012A-$2.95

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$9.94 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$3.63-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$60.24 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$0.81-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.03-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.38-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.94-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$1.15-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA